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A threshold level of NFATc1 activity facilitates
thymocyte differentiation and opposes notch-
driven leukaemia development
Stefan Klein-Hessling1, Ronald Rudolf1, Khalid Muhammad1, Klaus-Peter Knobeloch2,
Muhammad Ahmad Maqbool3, Pierre Cauchy4, Jean-Christophe Andrau3, Andris Avots1,
Claudio Talora5, Volker Ellenrieder6, Isabella Screpanti5, Edgar Serﬂing1 & Amiya Kumar Patra1,w
NFATc1 plays a critical role in double-negative thymocyte survival and differentiation.
However, the signals that regulate Nfatc1 expression are incompletely characterized. Here we
show a developmental stage-speciﬁc differential expression pattern of Nfatc1 driven by the
distal (P1) or proximal (P2) promoters in thymocytes. Whereas, preTCR-negative thymocytes
exhibit only P2 promoter-derived Nfatc1b expression, preTCR-positive thymocytes express
both Nfatc1b and P1 promoter-derived Nfatc1a transcripts. Inducing NFATc1a activity from P1
promoter in preTCR-negative thymocytes, in addition to the NFATc1b from P2 promoter
impairs thymocyte development resulting in severe T-cell lymphopenia. In addition, we show
that NFATc1 activity suppresses the B-lineage potential of immature thymocytes, and
consolidates their differentiation to T cells. Further, in the pTCR-positive DN3 cells, a
threshold level of NFATc1 activity is vital in facilitating T-cell differentiation and to prevent
Notch3-induced T-acute lymphoblastic leukaemia. Altogether, our results show NFATc1
activity is crucial in determining the T-cell fate of thymocytes.
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D
ifferentiation of CD4CD8 double-negative (DN) cells
to the CD4þ or CD8þ single-positive (SP) T cells in the
thymus is regulated by a complex network of signalling
pathways involving multiple transcription factors at various
stages of development. On the basis of their differentiation status,
DN thymocytes consist of four distinct populations, CD44þ
CD25DN1, CD44þCD25þDN2, CD44CD25þDN3 and
CD44CD25DN4 (ref. 1). DN3 thymocytes upon rearrange-
ment of their T-cell receptor b (Tcrb) locus express a functional
TCRb chain, which, in combination with the preTa (pTa) chain
forms the preTCR (pTCR). PreTCR signalling is essential for the
differentiation of DN3 cells to DN4 and later stages. We have
shown recently that the transcription factor NFATc1 plays
a critical role during early stages of thymocyte development2.
A haematopoietic lineage cell-speciﬁc ablation of NFATc1 activity
blocked thymocyte development at DN1 stage, the earliest stage
of thymic T-cell development2. Mice deﬁcient for NFATc2,
NFATc3 or both, do not show any apparent defect in thymocyte
development3,4, suggesting a critical role played by NFATc1
during thymic T-cell development.
Ligation of TCR with cognate peptide-MHC complex in vivo,
or stimulation of T cells with anti-CD3 plus anti-CD28 Abs
in vitro increases intracellular Ca2þ levels, which in turn
activate the serine/threonine phosphatase calcineurin. Active
calcineurin dephosphorylates multiple serine/threonine residues
in NFAT proteins and facilitates their nuclear translocation. We
have previously elucidated a novel NFAT activation pathway in
pTCR-negative thymocytes, which plays an indispensable
role in their survival and differentiation2. In contrast to
the calcineurin-mediated dephosphorylation pathway, in pTCR-
negative thymocytes IL-7-JAK3 signals activated NFATc1 via
phosphorylation of tyrosine371 in the regulatory domain2. Both,
the calcineurin-mediated ‘conventional’ and IL-7-JAK3-mediated
‘alternative’ pathways though explained the post-translational
mechanisms of NFAT activation, the transcriptional regulation of
Nfatc1 itself is poorly understood. A previous study showed
Nfatc1 expression in T cells is autoregulated by NFATc1 (ref. 5).
In this study, we have delineated the signalling pathways that
regulate Nfatc1 expression with distinct promoter usage at pTCR-
negative and -positive thymocytes. Further, we provide evidence
in support of a critical role of NFATc1 in suppressing lineage
plasticity of immature thymocytes towards non-T lineages, and
the essentiality of a threshold level of NFATc1 activity
at the pTCR-positive DN3 stage in facilitating the T-cell fate of
thymocytes by preventing the development of T-Acute
Lymphoblastic Leukaemia (T-ALL).
Results
Differential usage of Nfatc1 promoters in thymocytes. In
T cells, two distinct promoters, a distal (P1) and a proximal (P2),
initiate Nfatc1 expression. Due to alternative splicing and usage of
two different poly-adenylation (pA) sites, six Nfatc1 isoforms;
three from P1 promoter (Nfatc1aA, aB and aC) and three from
P2 promoter (Nfatc1bA, bB and bC), respectively, are synthesized
(Supplementary Fig. 1a)6,7. To distinguish whether any particular
NFATc1 isoform is prevalent in pTCR-negative and -positive
thymocytes we analysed wild-type (WT) DN1–DN4 cells for
Nfatc1 expression. Interestingly, we observed an exclusive P2
promoter activity in the pTCR-negative DN3 cells, whereas
pTCR-positive DN4 cells exhibited both P2 as well as P1
promoter activity (Fig. 1a; Supplementary Fig. 1b). Exclusive P2
activity in pTCR-negative thymocytes was supported by an active
chromatin conﬁguration, as indicated by histone modiﬁcations
and a concomitant recruitment of RNA polymerase II (Pol II) at
the Nfatc1 P2 promoter in Rag2 / DN3 cells, whereas only
little H3K4me3 was detectable at the P1 promoter (Fig. 1b).
Analysis of small RNA-seq data8, to score for bidirectional paused
transcripts enriched at promoters further conﬁrmed signiﬁcant
enrichment of transcriptional start site RNAs at P2 promoter over
P1 (Fig. 1b). Using an additional set of primers to detect total
a- or b-speciﬁc transcripts derived from the P1 or P2 promoters
respectively, again we observed an exclusive P2 activity in DN3,
and both P1 and P2 activity in DN4 cells (Supplementary Fig. 1c).
Further, in agreement with our observation regarding induction
of P1 promoter activity at the pTCR-positive stages, we detected
NFATc1a proteins in DN4 cells but not in DN3 cells (Fig. 1c;
Supplementary Fig. 1d). Keeping in view the ﬁndings of a
previous report5, that in naive T cells, constitutive basal level TCR
signalling maintains the P2 promoter activity, and TCR-antigen
ligation induced signals are responsible for the P1 promoter
activity, it was quite intriguing how thymocytes lacking even the
pTCR exhibit such a robust Nfatc1 expression.
To further substantiate our observation regarding selective
promoter usage, and the role of pTCR signalling in inducing P1
activity, we investigated three different mouse models, where
either there was no pTCR (Rag1 / ), pTCR was absent but a
downstream signalling molecule calcineurin was constitutively
active (Calcineurin transgenic; DCam)9 or there was enhanced
pTCR signalling (Notch3 transgenic; N3 tg)10. In both Rag1 /
and DCam mice, T-cell development is blocked at the DN3 stage
due to lack of pTCR signals9. In contrast, N3 tg mice showed an
enhanced DN3 to DN4 transition due to strong pTCR signals
(Fig. 1d,e). Conﬁrming our ChIP-Seq and RNA-Seq observations,
analysis of Nfatc1 expression in Rag1 / DN3 cells showed the
presence of only Nfatc1b isoforms (P2 activity), similar to that in
WT DN3 cells (Fig. 1f). Stimulating Rag1 / DN3 cells with
anti-CD3 Abs to mimic pTCR signalling, we readily detected
Nfatc1a transcripts in addition to the Nfatc1b transcripts
implying that pTCR signals can induce P1 promoter activity
(Fig. 1f). Further, P1 promoter activity was autoregulated by
NFATc1, as P1 activity disappeared without affecting P2 activity
when anti-CD3 antibodies stimulated Rag1 / DN3 cells were
treated with cyclosporine A (CsA; Fig. 1f). In contrast to the WT
and Rag1 / mice, DCam DN3 cells showed a robust P1 activity
in addition to the P2 promoter activity (Fig. 1g). The strong P1
activity in DCam DN3 cells was due to the autoregulatory loop
maintained by constitutive calcineurin activity, as CsA treatment
speciﬁcally extinguished Nfatc1 P1 activity without affecting the
P2 activity (Fig. 1g). Further, we observed a similar pattern of
strong P1 and P2 promoter activity as that in DCam mice, in N3
tg DN3 cells (Fig. 1h). Thus, it was evident that Nfatc1 is
expressed from distinct promoters in pTCR-negative and
-positive thymocytes, and pTCR signalling is necessary for the
induction of Nfatc1 P1 promoter activity.
NFATc1 activity is vital for DN thymocyte differentiation. Due
to exclusive P2 activity in pTCR-negative thymocytes, we inves-
tigated whether NFATc1b is solely critical for the differentiation
of early DN thymocytes. To clarify this, we have generated a
mutant mouse with ﬂoxed Nfatc1 P2 promoter element (P2ﬂ/ﬂ) to
abolish NFATc1b activity in a tissue-speciﬁc manner
(Supplementary Fig. 2a–d). We bred P2ﬂ/ﬂ mice with mice
expressing cre-recombinase under Vav promoter (Vav-Cre)11 to
abolish Nfatc1 P2 activity during thymocyte development.
Surprisingly, analysis of Vav-CreP2ﬂ/ﬂ mice showed completely
normal T-cell development, which was indistinguishable from
that of littermate controls (Fig. 2a–c; Supplementary Fig. 2e). The
normal T-cell development in Vav-CreP2ﬂ/ﬂ mice was quite
surprising, as loss of NFATc1 activity was expected to block
thymocyte development at the DN1 stage2. PCR with reverse
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transcription (RT–PCR) analysis on pTCR-negative thymocytes
showed a total lack of Nfatc1 P2-derived transcripts indicating
abolition of Nfatc1 P2 promoter activity (Fig. 2d). However,
NFATc1 activity was not lost rather in absence of P2 activity we
observed a robust P1 promoter activity in the Vav-CreP2ﬂ/ﬂ
pTCR-negative thymocytes (Fig. 2d).
We have previously shown that Bcl-2 is a target of NFATc1 in
pTCR-negative thymocytes2. However, analysis in Vav-CreP2ﬂ/ﬂ
DN3 cells showed similar levels Bcl-2 proteins as that in
littermate controls (Supplementary Fig. 2f), suggesting that
most likely NFATc1a and -b isoforms regulate a similar set of
target genes that are critical for early thymocyte survival and
differentiation. Thus, in the Vav-CreP2ﬂ/ﬂ mice, Nfatc1 P1
promoter activity functionally compensated for the loss of P2
activity, underlining the indispensability of NFATc1 activity in
thymocyte differentiation.
NFATc1 activity is essential for T-cell development. To inves-
tigate the physiological signiﬁcance of the distinct pattern of
NFATc1 promoter activity in pTCR-negative and -positive
thymocytes, we explored what impact NFATc1a will have on
thymocyte development if it is co-expressed with NFATc1b in
pTCR-negative thymocytes. To address this issue, we used mice
in which a constitutively active version of Nfatc1aA was knocked-
in into Rosa-26 locus ﬂanked by a ﬂoxed stop cassette
(R26-caNfatc1aA-Stopﬂ/ﬂ: designated hereafter as Nfatc1aAﬂ/ﬂ)12.
To activate Nfatc1aA expression in early thymocytes we bred
Nfatc1aAﬂ/ﬂ mice with Vav-Cre mice. Surprisingly, analysis of
Vav-CreNfatc1aAﬂ/ﬂ mice showed severely impaired thymocyte
development as evident from a dose-dependent reduction in the
size of the thymus, spleen and lymph nodes (Fig. 3a).
Accordingly, the cellularity in these organs was drastically
reduced in Vav-CreNfatc1aAﬂ/ﬂ mice leading to T-cell
lymphopenia (Fig. 3b,c). Analysis of DN cells from
Vav-creNfatc1aAﬂ/ﬂ mice to understand the reason behind the
low thymic cellularity revealed a dose-dependent block in the
transition of DN3 cells to the DN4 stage (Fig. 3d; Supplementary
Fig. 3a). Conﬁrming our earlier report regarding NFATc1-
mediated regulation of Bcl-2 expression in developing DN
thymocytes, enforced NFATc1a expression enhanced Bcl-2
levels in Vav-CreNfatc1aAﬂ/ﬂ DN3 cells compared with WT
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Figure 1 | Differential induction of Nfatc1 P1 and P2 promoters in pTCR-negative and -positive thymocytes. (a) RT–PCR analysis of Nfatc1 isoforms
expression in WT DN3 and DN4 cells. (b) ChIP-Seq and small RNA-Seq analysis of Nfatc1 gene for histone methylation, acetylation, RNA Polymerase II
binding and bidirectional transcriptional start site RNA at the P1 and P2 promoter region in Rag2 / DN3 cells. Blue rectangles highlight promoters,
whereas pink rectangles show putative enhancer hallmarks based on the presence of epigenetic/transcriptional features. Chromosomal coordinates
represented below are the ones corresponding to DNase I hypersensitive sites described in Fig. 6a that are both inside the highlighted areas.
(c) Immunoﬂuorescence analysis of NFATc1a distribution in WT DN3 and DN4 cells. Nuclear staining was revealed by DAPI. Scale bar, 10mm.
(d) Flow cytometry proﬁles of DN1 to DN4 cells distribution in indicated mice. (e) Intracellular TCRb staining in WT, DCam and N3 tg DN3 cells.
(f) RT–PCR analysis reveals the expression of six Nfatc1 isoforms in DN3 cells from Rag1 / mice either freshly sorted, or treated with anti-CD3 Abs in
absence or presence of CsA for 12 h. (g) Transcript levels of six Nfatc1 isoforms in freshly isolated or 12 h CsA-treated DN3 cells from DCam mice.
(h) Pattern of Nfatc1 isoforms expression in freshly sorted DN3 and DN4 cells from N3 tg mice. Numbers within each dot plot or histogram represent
per cent respective population. Data are representative of three independent experiments.
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cells (Fig. 3e). This observation further suggests that the reduced
thymic cellularity in the Vav-creNfatc1aAﬂ/ﬂ mice was not
because of an increase in cell death of the DN thymocytes. Similar
to the DCam mice9, enforced NFATc1aA expression in DN3 cells
resulted in the lack of rearranged TCRb expression (Fig. 3f),
leading to the loss of pTCR signalling, although the expression of
CD3e a component of the pTCR complex remained unaffected
(Supplementary Fig. 3b). In addition, NFATc1aA activity in
pTCR-negative cells strongly retarded their rate of differentiation
to the double-positive (DP) and later stages. In in vitro co-culture
assays on OP9-DL1 (bone marrow stromal cells expressing Notch
ligand delta-like 1) monolayer, Vav-CreNfatc1aAﬂ/ﬂ DN1–DN4
cells showed inefﬁcient differentiation to DP stage compared with
the cells from WT mice (Fig. 3g). These observations suggest that
the combined activity of NFATc1a and NFATc1b, or rather an
increase in total NFATc1 activity, before pTCR-positive stages is
detrimental for T-cell development.
To rule out the possibility that the negative impact on
thymocyte development in the Vav-CreNfatc1aAﬂ/ﬂ mice was
due to an excess in NFATc1 activity derived from both the
endogenous as well as the transgene, we generated a mouse model
where only NFATc1aA was expressed without any contribution
from the endogenous Nfatc1 gene. We bred Vav-CreNfatc1aAﬂ/ﬂ
mice with Nfatc1ﬂ/ﬂ mice to eliminate all NFATc1 activity
derived from the endogenous Nfatc1 gene. Analysis of
Vav-CreNfatc1aAﬂ/ﬂNfatc1ﬂ/ﬂ mice revealed that even in the
absence of any endogenous NFATc1, NFATc1a activity derived
from the knocked-in gene only resulted in a similar block in
thymocyte differentiation at the DN3 stage compared with
littermate controls (Supplementary Fig. 3c,d), as observed in the
Vav-CreNfatc1aAﬂ/ﬂ mice. This could still be due to an above
threshold level of NFATc1 activity derived from the transgene.
Thus, from our analysis it is apparent that a certain threshold
level of NFATc1 activity is essential for T-cell development.
NFATc1 suppresses lineage plasticity of immature thymocytes.
T-cell development in the thymus follows a sequential process of
T-lineage speciﬁcation, and commitment. While DN1 cells retain
the potential to differentiate into B cells, natural killer (NK) cells,
dendritic cells (DCs) and macrophages, the lineage plasticity gets
restricted to NK and DC lineages in DN2 cells, and ﬁnally is
completely lost at the DN3 stage13. Accordingly, only in WT DN1
cells we observed Ebf1 and Pax5 expression necessary for B-cell
development, whereas, expression of Id2 necessary for NK cell, or
Spf1 (PU.1), Csf1r and Cebpa, necessary for myeloid-lineage
development were maintained in DN2 cells (Fig. 4a). We assumed
that NFATc1b activity most likely play a role in suppressing the
lineage plasticity during DN1 to DN3 differentiation and thereby
consolidate T-lineage commitment. To investigate this possibility,
we analysed lineage-speciﬁc gene expression in DN1–DN4 cells
from Vav-CreP2ﬂ/ﬂ mice. We observed a similar suppression of
lineage plasticity towards non-T lineages in the absence of
NFATc1b activity (Fig. 4b), as in the WT mice (Fig. 4a). As in the
Vav-CreP2ﬂ/ﬂ mice P1 promoter-driven NFATc1a activity
compensated for the loss of NFATc1b during T-cell
development, we concluded that a threshold level of NFATc1
activity irrespective of any particular isoform might be crucial in
suppressing lineage plasticity and thereby facilitate T-lineage
commitment.
DN1 cells are a heterogeneous population, and based on CD24
(heat-stable antigen) and CD117 (c-Kit) expression they are
characterized to have ﬁve distinct populations termed as DN1a,
DN1b, DN1c, DN1d and DN1e (ref. 13). DN1a and DN1b cells
maintain highest lineage plasticity, whereas, DN1d and DN1e
cells are more speciﬁed to take the T-cell lineage. We presumed
that the combined activity of NFATc1a, and NFATc1b
is essential for irreversible T-lineage commitment at the
pTCR-positive stage, and NFATc1a if expressed along with
NFATc1b early at the pTCR-negative stages will suppress the
lineage plasticity more effectively. Interestingly, analysis of
Vav-CreNfatc1aAﬂ/ﬂ mice showed a strong reduction in DN1a
and DN1b populations compared with littermate WT mice
(Fig. 4c,d). Accordingly, we observed a dose-dependent speciﬁc
loss of B cells in the thymus from Vav-CreNfatc1aAﬂ/ﬂ mice
compared to WT mice whereas, NK, DC or macrophage lineages
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were not affected (Fig. 4e). Corroborating this, Ebf1 and Pax5
expression were suppressed in Vav-CreNfatc1aAﬂ/ﬂ DN1 cells,
whereas gene expression necessary for NK and myeloid lineages
was unaffected (Fig. 4f). However, the suppression of B-lineage
potential of the Vav-CreNfatc1aAﬂ/ﬂ DN1 cells was neither due
to enhanced cell death nor due to any toxic effect of NFATc1
activity on the precursor cells. In a B-lineage permissible
environment, FACS sorted DN1 thymocytes from Vav-CreNfat-
c1aAﬂ/ﬂ mice developed comparable proportion of B220þ B cells
as that in case of WT DN1 cells, when co-cultured on OP9 bone
marrow stromal cell layer (Supplementary Fig. 3e). This
observation ruled out that there was any inherent developmental
restriction towards B-lineage differentiation in the Vav-CreNfat-
c1aAﬂ/ﬂ DN1 cells.
Integrin signalling induces Nfatc1 P2 promoter activity. The
exclusive P2 activity in the WT pTCR-negative thymocytes led us
to ask how the P2 promoter is regulated in these cells. Surpris-
ingly, when we cultured DN4 thymocytes in vitro, not only all
P1-directed transcripts disappeared but we also observed the
absence of all P2-derived transcripts as well (Fig. 5a). However,
annexin V analysis revealed that majority of cells in this culture
condition were alive, ruling out cell death being the reason for the
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loss of Nfatc1 expression (Supplementary Fig. 4a). We have
previously reported the responsiveness of Nfatc1 promoter
activity to Forskolin (FSK) treatment in vitro5. To investigate
whether cyclic-AMP (cAMP) signalling is responsible for Nfatc1
P2 activity, we treated WT DN3 and DN4 cells with a cAMP
analogue 8-CPT-cAMP. Interestingly, 8-CPT-cAMP treatment
speciﬁcally induced the expression of Nfatc1b, both in DN3 and
DN4 cells (Fig. 5b). To prove that P2 activity is cAMP signalling-
dependent, we explored for a physiological context where the
intracellular cAMP level is high. Several recent studies have
reported increased cAMP levels in CD4þCD25þFoxp3þ
regulatory T (Treg) cells14–16. The effect of cAMP in inducing
Nfatc1 P2 promoter activity was conﬁrmed as Treg cells exhibited
stronger P2 promoter activity compared with CD4þCD25-
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Foxp3- effector T (Teff) cells (Fig. 5c). This observation was
corroborated with higher level of green ﬂuorescent protein (GFP)
expression reﬂecting higher NFATc1 levels in Treg cells against
Teff cells from Nfatc1-eGfp-Bac tg reporter mice17 (Fig. 5d).
Next, we investigated which signalling pathway is involved in
generating intracellular cAMP that drives Nfatc1 expression in
thymocytes and in T cells. Cell–cell interaction is mediated by
various integrins, and thymocytes, as well as T cells express a
number of integrins. CD2 (LFA-2) expressed on thymocytes and
T cells has been shown to activate T cells18,19. Murine CD2 binds
to its ligand CD48 expressed on T cells as well as on the
interacting cells and thereby can transduce signals both in cis and
in trans20–23. In addition, CD2 signalling in T cells have been
reported to induce cAMP24,25, and thereby the activation of
cAMP response element binding (CREB) proteins26. Mice lacking
cAMP-CREB signalling show impaired thymocyte proliferation
and altered fetal T-cell development27,28. To check whether CD2-
CD48 interactions regulate Nfatc1 expression in DN thymocytes,
we analysed CD2 and CD48 expression on various thymocyte
subsets. We observed only a fraction of DN thymocytes expressed
CD2 on their surface, which was increased in DP and SP
thymocytes as well as in peripheral T cells (Fig. 5e). However,
CD48 expression was highest on DN cells and lowest in DP and
CD4þ SP cells (Fig. 5f). Among DN thymocytes, DN1 cells
expressed the highest level of CD2, whereas CD48 expression was
high on all pTCR-negative DN populations (Fig. 5g,h). To prove
whether CD2-CD48 signals could induce Nfatc1 expression, we
stimulated WT DN3 cells with CD48 antibodies and analysed for
the generation of P1- and P2-directed transcripts. CD48
stimulation at a higher concentration induced the synthesis of
both P1- and P2-directed Nfatc1 transcripts in DN3 cells,
while stimulation with PMA, reported to substitute CD2
co-stimulation29, did not generate any Nfatc1 RNA (Fig. 5i).
However, CD48 at low concentration only induced Nfatc1 P2
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activity in the pTCR-negative thymocytes unraveling the effect of
signal strength on the inducibility of P1 and P2 promoters
(Supplementary Fig. 4b).
Although CD2-CD48 signalling induced Nfatc1 expression
in vitro, these are unlikely to be the only integrins responsible for
Nfatc1 expression in vivo. This was supported by the reported
normal T-cell development in Cd2 / mice30–32, as well as in
mice injected with anti-CD2 antibodies33, and also in Cd48 /
mice34, indicating the involvement of additional integrins in
regulating Nfatc1 expression. Accordingly, analysis of thymocytes
and T cells showed a differential expression pattern for various
integrins (Supplementary Fig. 4c; Fig. 5j). CD4þCD25þ Treg
cells both in the thymus and in LNs expressed much higher levels
of various integrins compared to CD4þCD25 Teff cells (Fig. 5k;
Supplementary Fig. 4d), concurring with our observation
regarding higher Nfatc1 expression in Treg cells over Teff cells
(Fig. 5c). Among the CD4þCD25þ population, CD25hi cells
expressed highest level of various integrins, the most prominent
being CD18, CD48, CD49d and CD62L (Supplementary
Fig. 5a,b). This integrin expression pattern directly correlated to
that of Nfatc1 expression in CD25hi cells as revealed from higher
GFP levels in the Nfatc1-eGfp-Bac transgenic reporter mice
(Supplementary Fig. 5c). To further consolidate our observation,
we stimulated WT CD4þ T cells with ﬁbronectin, the ligand for
CD18. Interestingly, ﬁbronectin stimulation induced robust
Nfatc1 expression, which was mainly derived from the P2
promoter (Fig. 5l). In addition, similar to that in DN3 thymocytes
(Fig. 5i), CD2-CD48 signalling also induced Nfatc1 P2 activity in
peripheral CD4þ T cells (Fig. 5l). Thus, the above observations
established integrin-cAMP signalling as a critical component in
regulating Nfatc1 gene expression in thymocytes and in T cells.
An intronic cis-regulatory element controls P1 activity.
To address the question why P1 promoter is inactive in the
pTCR-negative thymocytes, we analysed DNA methylation status
at the P1 promoter in these cells. However, methylation analysis
did not reveal any signiﬁcant difference between WT DN3 and
DN4 cells (Supplementary Fig. 6a). To investigate whether
epigenetic modiﬁcations on pTCR signalling at the DN3 to DN4
transition induce P1 activity we performed ChIP-Seq analysis of
Rag2 / DN3 cells stimulated with anti-CD3 Abs to mimic
pTCR signals. However, no additional epigenetic changes
were detected at the P1 promoter in the anti-CD3 stimulated
Rag2 / DN3 cells compared to the unstimulated cells
(Supplementary Fig. 6b; Fig. 1b). These observations suggested
that P1 promoter induction still requires involvement of addi-
tional cis-regulatory elements and/or trans-acting factors. To
identify cis-regulatory elements essential for P1 promoter activity,
we studied the DNase I hypersensitivity analysis of the human
NFATc1 locus (Roadmap Epigenomics Project, www.roadmape-
pigenomics.org). Besides the P1 and P2 promoter elements, two
very distinct DNase I hypersensitive sites designated as E1 and E2
were evident in the intron between exons 10 and 11 in the
CD34þ human haematopoietic stem cells (Fig. 6a). Signiﬁcantly,
these elements were tissue-speciﬁc as compared with the hema-
topoietic stem cells, CD3þ human T cells showed only the
presence of E2 site, which was conserved in murine T cells as well
(Fig. 6a).
To investigate the inﬂuence of E1 and E2 elements on Nfatc1
expression, we generated luciferase reporter constructs with the
P1 or P2 promoter in combination with the E1 or E2 element
(Fig. 6b). On stimulation with PMAþ Ionomycin (I), in EL-4
thymoma cells the E2, but not the E1 element induced a strong
Nfatc1 P1 promoter activity compared with a mild increase in P2
promoter activity (Fig. 6b). We also tested two additional DNAse
I hypersensitive sites, E3 positioned in the intron between exons 3
and 4, and E4 positioned at the extreme 30 region of Nfatc1 locus
for their potential regulatory effect on Nfatc1 promoter activity.
However, both these elements were ineffective in inducing Nfatc1
P1 promoter activity (Supplementary Fig. 6c), suggesting the
essentiality of the E2 element in the context of P1 promoter
activity.
To extend our characterization of the E2 enhancer, we analysed
for the trans-acting factors, which might play a role in enhancing
the E2-mediated P1 promoter activity. We detected binding
motifs for three prominent lymphoid-speciﬁc transcription
factors; NFATc1, GATA3 and PU.1 in the E2 element
(Supplementary Fig. 6d). To investigate whether any of these
factors positively modulates the E2 enhancer activity, we mutated
the binding sites for individual factors and checked their
enhancer potential for Nfatc1 P1 promoter activity. In reporter
assays, only the NFATc1 mutant showed loss of enhancer activity,
whereas GATA3 or PU.1 mutants exerted no inﬂuence on Nfatc1
P1 promoter activity (Supplementary Fig. 6d). This was in line
with the previous reports from our laboratory that NFATc1
autoregulates the P1 promoter activity5, however, the
involvement of the E2 element was hitherto unknown.
Further, to study the effect of E2 element on Nfatc1 promoter
in vivo, we generated Nfatc1-eGfp-Bac-DE2 tg reporter mice by
deleting 1Kb DNA from intron 10 harbouring the E2 element
(Supplementary Fig. 6e)17. Loss of E2 enhancer activity in Nfatc1-
eGfp-Bac-DE2 tg reporter mice, showed a clear reduction in
Nfatc1 expression in CD4þ T cells as evident from reduced GFP
expression both in unstimulated as well as in stimulated cells
compared with that in the Nfatc1-eGfp-Bac tg reporter mice
(Fig. 6c). This reduction in NFATc1 levels was due to a speciﬁc
loss of P1-derived NFATc1a, as we observed a strong decrease in
NFATc1a proteins in immunoblot analysis with antibodies
against GFP as well as NFATc1a, whereas loss of E2 enhancer
activity did not inﬂuence NFATc1b protein levels (Fig. 6d;
Supplementary Fig. 7). Thus, we have identiﬁed a novel
cis-regulatory element E2, acting as an enhancer, speciﬁcally for
the P1 promoter activity in T cells.
NFATc1 activity prevents experimentally induced T-ALL. At
the DN3 stage, though pTCR signalling is vital for proliferation
and differentiation of thymocytes, it is equally crucial that the
pTCR signals are switched off in the differentiated cells. Failure to
do so will lead to the development of T-ALL, an aggressive
form of leukaemia observed in both mouse and humans with
constitutive Notch signalling35–40.
We have previously shown that T-cell development in DCam
mice is severely blocked at DN3 stage due to a defect in pTCR
formation9. Further analysis revealed a strong downregulation in
Ptcra (pTa) expression (Fig. 7a), in DCam DN3 cells. Ptcra
expression is regulated by Notch signalling41, and accordingly, in
N3 tg T cells pTa expression is not extinguished38. The negative
effect of NFATc1a on Ptcra expression in DCam DN3 cells
suggests that Nfatc1 P1 activity might be involved in
downregulating pTa expression once the cells have received
pTCR signals. Inhibition of NFATc1 activity by CsA treatment
restored Ptcra expression in DCam DN3 cells (Fig. 7b), further
strengthening the possibility that NFATc1a suppresses Ptcra
expression. This was conﬁrmed by a dose-dependent suppression
of Ptcra expression in DN4 cells in Vav-CreNfatc1aAﬂ/þ and
Vav-CreNfatc1aAﬂ/ﬂ mice compared with WT cells (Fig. 7c).
Further, ChIP assays conﬁrmed NFATc1a binding at the Ptcra
promoter in vivo in WT DN and DCam DN3 cells (Fig. 7d). Also,
in reporter assays NFATc1a failed to induce Ptcra promoter
activity whereas, it efﬁciently activated the murine Il2 promoter
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(Fig. 7e). However, in human T-ALL cell line Jurkat, in reporter
assays we observed a strong downregulation in Notch-induced
Ptcra promoter activity by NFATc1a (Fig. 7f). Thus, our
observations suggest that Nfatc1 P1 activity critically inﬂuences
Notch-pTCR signalling, necessary for normal T-cell development.
If this is the case, modulation of Nfatc1 P1 activity might help
to prevent T-ALL pathogenesis. We used N3-induced T-ALL as a
model to check the role of NFATc1 in T-ALL development. N3 tg
mice developed severe T-ALL with CD4CD8CD44CD25þ
DN3 cells accumulating in the thymus and peripheral lymphoid
organs (Fig. 7g). As a result of tumorigenic transformation the
differentiation of DN3 cells to T cells was drastically blocked in
N3 tg tumour mice (Fig. 7g). Interestingly, Nfatc1 expression in
these N3-induced T-ALL cells was strongly downregulated
compared with WT DN3 cells (Fig. 7h). We hypothesized that
if the suppressed Nfatc1 expression is the ‘cause’ and not the
‘effect’ of T-ALL, then restoring NFATc1 activity in N3 tg mice
will help prevent leukemogenesis. To check this possibility
in vivo, we crossed DCam mice with N3 tg mice to generate
DCamN3 double-tg mice. Surprisingly, in contrast to N3 tg
mice, none of the DCamN3 double-tg mice analysed, showed
any sign of T-ALL (Fig. 7i). Rather, the double-tg mice showed a
thymic phenotype similar to that observed in DCam mice (Fig. 7i;
Supplementary Fig. 8a). Importantly, in DCamN3 double-tg
mice even though thymocytes were accumulated at the DN3 stage
(Supplementary Fig. 8b), still they were not tumorigenic
suggesting a strong tumour-preventing activity of NFATc1 in
this experimental model.
Discussion
We have shown previously the indispensability of NFATc1
activity in early thymocyte development2. Here we have
delineated the signals that control Nfatc1 expression initiated
from two distinct promoters in a thymocyte developmental stage-
speciﬁc manner and, how NFATc1 activity simultaneously
facilitates the T-cell fate of the thymocytes, and prevents the
pathogenesis of T-ALL. The ﬁnding that NFATc1 expression
directed from only P2 promoter at the pTCR-negative stages and
from both P1 and P2 promoters at the pTCR-positive stages
establish the differential threshold of NFATc1 activity required
for thymocyte differentiation. Once the DN3 cells receive pTCR
signals, they are irreversibly committed towards T-lineage only.
Hence, the NFATc1a activity at the pTCR-positive stages is the
key to enhance the threshold of total NFATc1 activity through
which T-lineage commitment is established on pTCR signals.
Thus, the switch from ‘NFATc1b only’ to both ‘NFATc1a and b’
at the pTCR-positive DN3 cells is absolutely necessary for
T-lineage commitment in the thymus. In this regard our
observation that NFATc1 activity speciﬁcally suppresses the
B-lineage plasticity of the immature thymocytes provides an
important clue as to how activities of various transcription factors
stabilize T-cell fate during development. Importantly, the
characterization of a novel enhancer element speciﬁcally
regulating the P1 promoter activities holds immense
signiﬁcance in the context of T-lineage commitment. From our
observations, it appears that epigenetically E2 element is in an
open conformation at the DN3 stage, but it is the speciﬁc
transcription factor occupancy, which is critical in inducing P1
promoter activity at the pTCR-positive stage. As we have shown
earlier that NFATc1 nuclear levels increases from DN1 to DN3
stage thus, most likely making it possible to bind to the E2
element and autoregulates its own expression by inducing P1
promoter activity. The elucidation of the signalling pathways
regulating Nfatc1 gene regulation will help to better understand
T-cell development and will provide insight for therapeutic mani-
pulations of NFATc1 activity to achieve immune reconstitution
in situations like T-cell lymphopenia (Supplementary Fig. 8c).
The loss of Nfatc1 expression in in vitro cultures though quite
intriguing was not due to an enhanced cell death of the immature
thymocytes (Supplementary Fig. 4a). Rather, because of very
small number of sorted cells their density was too low in the
in vitro cultures, which led not only to a lack of interaction
between thymocytes and the thymic stroma, but it also resulted in
a loss of interaction among thymocytes themselves. In the normal
thymus, millions of thymocytes are very densely packed into the
available space, which facilitates both thymocyte-stroma and also
thymocyte–thymocyte interactions. In our opinion both types of
interactions provide the signals essential for Nfatc1 expression. In
line with this Nfatc1 expression was not lost when thymocytes
were cultured in vitro at a higher density.
We have previously reported a severe T-cell lymphopenia in
mice lacking NFATc1 activity in the early thymocytes2. Here we
show overexpression of NFATc1 also results in T-cell
lymphopenia (Fig. 3a-c; Supplementary Fig. 8c), indicating a
threshold level of NFATc1 activity is critical for T-cell
development. The increase in total NFATc1 activity in the
Vav-CreNfatc1aAﬂ/ﬂ mice not only prevented the differentiation
of DN3 cells to DN4 stage (Fig. 3d) but it also severely affected
several key T-cell-speciﬁc genes expression. The dose effect of
NFATc1, not only on the DN thymocyte development, but also
on the DP to SP differentiation is clearly reﬂected in
the cellularity of the thymus, LNs and spleen in the
Vav-CreNfatc1aAﬂ/ﬂ mice compared with WT mice (Fig. 3b,c)
underlining the inﬂuence of NFATc1 activity on thymic T-cell
development.
Our results from DCamN3 double-tg mice show the tumour
suppressor activity of NFATc1 in the experimental setting of
hyperactive Notch, as it prevented T-ALL development despite
these mice having constitutive Notch3 signalling. In vivo, once the
DN3 cells receive pTCR signals they undergo a limited cell cycle
and differentiate to DN4 stage (Supplementary Fig. 8c). Unless
the pTCR signalling is switched off, it will lead to uncontrolled
proliferation resulting in T-ALL development (Supplementary
Fig. 8c). To prevent pTCR formation, Ptcra expression needs to
be silenced. Here we show that NFATc1a activity suppresses the
Ptcra expression (Fig. 7a–c,e,f). As Nfatc1 P1 activity is initiated
only at the pTCR-positive thymocytes and pTCR signals induce
NFATc1 activation42, this is most likely the natural-feedback
mechanism to suppress pTCR expression and thereby prevent
T-ALL development once the cells have received optimal pTCR
signals (Supplementary Fig. 8c). However, loss of function
mutations involving NFAT has not been reported in
spontaneous cases of either human or murine T-ALL; thus, the
tumour suppressive activity of NFATc1 may be speciﬁc to the
background of the additional oncogenic events. Altogether, our
study shows that a threshold level of NFATc1 activity is critical
for T-cell development. Any alteration, such as above or below
threshold levels of NFATc1 activity will push the delicate
balance towards an unwanted extreme, either resulting in
T-cell lymphopenia or, likely in combination with other
oncogenic events, leading towards the development of
leukaemia (Supplementary Fig. 8c).
Methods
Mice. C57BL/6 WT, calcineurin tg (DCam), Rag1 / , Notch3 tg (N3 tg),
CamN3 tg, Nfatc1 P2ﬂ/ﬂ, Vav-CreNfatc1P2ﬂ/þ , Vav-CreNfatc1P2ﬂ/ﬂ, R26-caN-
fatc1aA-Stopﬂ/ﬂ (Nfatc1aAﬂ/ﬂ), Vav-CreNfatc1aAﬂ/þ and Vav-CreNfatc1aAﬂ/ﬂ,
Nfatc1-eGfp-Bac tg, Nfatc1-eGfp-Bac-DE2 tg, Vav-CreNfatc1ﬂ/ﬂ and Vav-CreNfat-
c1aAﬂ/ﬂNfatc1ﬂ/ﬂ mice of 3–8 weeks age were used in this study. Double-mutant
mice such as, Vav-CreNfatc1P2ﬂ/ﬂ, Vav-CreNfatc1aAﬂ/ﬂ and Vav-CreNfatc1ﬂ/ﬂ
mice were generated by breeding corresponding ﬂoxed mice with Vav-Cre tg mice,
or by breeding DCam with N3 tg (DCamN3) mice, and the triple-mutant
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Vav-CreNfatc1aAﬂ/ﬂNfatc1ﬂ/ﬂ mice were generated by crossing Vav-CreNfatc1
aAﬂ/ﬂ mice with Nfatc1ﬂ/ﬂ mice. All mice were on BL/6 background and were
maintained in the animal facility of the Institute of Pathology or in the central
animal facility (ZEMM) of University of Wuerzburg, according to the institutional
guidelines.
Generation of Nfatc1 P2ﬂ/ﬂ mice. To generate the Nfatc1 P2 promoter ﬂoxed
allele, the 50 end of the murine NFATc1 cDNA was used to isolate genomic cosmid
clones of the Nfatc1 gene. The 8.5 kb XbaI fragment containing the Nfatc1 P2
promoter was identiﬁed in DNase I hypersensitive site analysis. The blunt ended
left (XbaI to XhoI) and right (XhoI to XbaI) arms were subcloned into the SmaI site
of pGL3 basic vector. To incorporate the loxP sites into the left or right arm, loxP
sites cut out from the pBS112 SX vector were inserted into the NdeI (448 bp),
Eco72I (5,020 bp) and NdeI (7536 bp) sites, respectively. The pTKNeoloxP plasmid
containing the neomycin (neo) gene for positive selection and thymidine kinase
gene for negative selection was used as basic vector in constructing the targeting
vector. Embryonic stem cell clones positive for the targeted P2 ﬂoxed allele were
selected and were used to generate the chimeric Nfatc1 P2ﬂ/ﬂ mice by blastocyst
injection method. Genomic tail DNA from the chimeric mice was analysed by
long-distance PCR to conﬁrm the genomic integration of the ﬂoxed Nfatc1 P2
allele, and mice were bred with C57BL/6 mice for several generations. WT, Nfatc1
P2ﬂ/þ and Nfatc1 P2ﬂ/ﬂ mice were genotyped using the following primers:
50-TCTCCACCTGACTTTCTGTTCC-30 (forward) and rev: 50-CTCTTCCCAA
TGGTTGTCTCTC-30 (reverse).
Generation of Nfatc1-eGfp-Bac-DE2 tg mice. Nfatc1-eGfp-Bac-DE2 construct was
generated by deletion of a 1-kb fragment of the E2 element from the original
Nfatc1-eGfp-Bac transgene cassette17. The BAC RP23-361H16 containing the
murine Nfatc1 gene (mm9 chr.18, 80.779.051-80.993617, 214 kb) was further
modiﬁed using bacterial homologues recombination to delete 1,000 bp from the
intron 10 (mm9 chr.18, 80.809.298–80.808.298, DE2). Two homology arms
ﬂanking the region of interest were generated by PCR using the primers 50-targ-
box-E2_for: 50-AAGGCGCGCCAAGAGGACCGGAACTCTGTG-30 , 50targ-
box-E2_rev: 50-GCAGTGTCTATGGCTGTGCAAATCACCTG-30 , 30targ-box-
E2_for: 50-TGCACAGCCATAGACACTGCAAGTCAGGG-30 , and 30targ-box-
E2_rev: 50-AAGCGGCCGCCTCCACACACACACATATCC-30 . In a second PCR,
the primers 50targ-box-E2_for and 30targ-box-E2_rev ampliﬁed a fusion product
that was cloned as an AscI and NotI fragment into the shuttle vector pLD53.RecA.
After homologous recombination the linearized BAC DNA was microinjected into
blastocysts. Mice tail biopsies were tested by PCR for BAC integration and for
deletion of the E2 element with the primers mNc1-DE2-for: 50-CATACAA
ACCCACAAGTGACCA-30 and mNc1-DE2-rev: 50-GAGCCCTACTGAGAG
ATGGGAA-30 (522 bp). The 50-end of integrated BAC DNA was detected with the
primer pair 50BAC(T7) for: 50-GGTCCATCCTTTTGTCTCA-30 and 30e3.6(T7)
rev: 50-CGAGCTTGACATTGTAGGA-30 (512 bp), and the 30 end with the primers
50e3.6(SP6) for: 50-CGTCGACATTTAGGTGACA-30 and 30BAC (SP6) rev:
50-CCATCGTTCCCTGACTCA-30 (439 bp).
Antibodies and ﬂow cytometry. All Abs used were purchased from BD
Pharmingen or from eBioscience: anti-CD4 (GK1.5), anti-CD8a (53-6.7),
anti-CD25 (PC61), anti-CD44 (IM7), anti-CD2 (RM2-5), anti-CD3e (145-2C11),
anti-CD5 (53-7.3), anti-B220 (RA3-6B2), anti-CD11a (2D7), anti-CD11c (N418),
anti-CD18 (C71/16), anti-CD24 (M1/69), anti-CD48 (HM48-1), anti-CD49d
(R1-2), anti-CD62L (MEL-14), anti-TCRb (H57-597), anti-c-Kit (2B8), anti-NK1.1
(PK136), anti-F4/80 (BM8), anti-Gr1 (RB6-8C5), anti-Ter119 (TER-119), anti-c-
Kit (2B8), Annexin V, anti-Bcl-2 (3F11) and Hamster IgG1 Isotype control
(A19-3). Biotinylated antibodies were revealed with Streptavidin-Allophycocyanin
(APC) or Phycoerythrin-Cy5 (PE-Cy5). For surface staining all primary and
secondary antibodies were diluted at 1:300 in PBS containing 0.1% bovine serum
albumin (BSA) and 0.01% sodium azide. Cell death analysis of DN4 cells cultured
overnight in medium was performed by Annexin V (1:100) staining following
manufacturer’s instruction (BD Pharmingen). Flow cytometry was performed
according to standard protocol using FACSCalibur and CellQuest or FlowJo
software.
Cell sorting. For FACS sorting of DN1 to DN4 cells, DN thymocytes were enri-
ched by treatment of total thymocytes with biotinylated Abs against CD4 (GK1.5),
CD8 (TiB105), NK1.1 (1D4), CD19 (1D3) and MHC class II (2G9) followed by
negative selection using Anti-Biotin MicroBeads (Miltenyi Biotec). Purity of DN
cells was always 90–95% as veriﬁed by FACS analysis. Enriched DN thymocytes
were further stained with APC-conjugated CD4 and CD8, PE-conjugated CD25
and FITC-conjugated CD44 Abs to sort the DN1–DN4 cells gating on the
CD4CD8population using a FACSVantage or FACSAria (BD Biosciences) ﬂow
cytometer.
Intracellular staining. Total thymoctyes of 1 106 were ﬁrst surface
stained for CD4, CD8, and CD25 molecules. Afterwards, cells were ﬁxed in 1%
paraformaldehyde (15min at room temperature) and permeabilized in PBA
(1 PBS, 5% BSA and 0.02% NaN3) containing 0.5% saponin (10min at room
temperature). After permeabilization cells were incubated with FITC conjugated
mAbs against TCRb (1:100), CD3e (1:100), Bcl-2 (1:50) or Hamster IgG1
Isotype control (1:5) diluted in PBA containing 0.5% saponin for 60min at room
temperature. Cells were washed twice in 1ml of PBA/0.5% saponin, once with
PBS/0.1% BSA/0.01% azide and analysed by FACS.
Immunoﬂuorescence staining and ChIP assays. Sorted WT DN1þDN2þDN3
or DN4 cells were ﬁxed in 0.5% formaldehyde, followed by cytospin on to glass
slides at 300 r.p.m. for 3min. Cells were incubated with anti-NFATc1a (Immu-
noGlobe; IG-457), followed by Alexa Fluor 555–conjugated donkey anti-rabbit IgG
(A-31572; Molecular Probes) and DAPI (4,6-diamidino-2-phenylindole; Molecular
Probes). Image acquisition and analysis were done with a TCS SP2 Leica confocal
microscope and software.
ChIP assays on WT DN thymocytes, or Rag1 / and DCam DN3 cells with
anti-NFATc1 (Santacruz; sc-7294), anti-NFATc1a, antiRBPJk (Cell Signaling;
5313) and anti-IkB-a (Santa Cruz; sc-371) were done as described previously2.
Brieﬂy, 1 107 freshly isolated DN thymocytes from WT, or DN3 cells from
Rag1 / and DCam tg mice were cross-linked using 1% formaldehyde. Isolated
nuclei were sonicated so that the average length of chromosomal DNA became
500–750 bp. Chromatin solution was precleared with Sepharose G, and chromatin
was immunoprecipitated by incubating with 6–8mg of each antibody mentioned
above for overnight at 4 C. Immune complexes were collected on protein
G-Sepharose beads and immunoprecipitates were eluted with 1% SDS, 50mM
NaHCO3. After reversal of cross-links and deproteination, puriﬁed DNA was used
for ampliﬁcation of the Ptcra promoter region bound to NFATc1, NFATc1a, and
RBPJk with the following primers: 50- AGGGAACAGAATTCAAGGCTG-30
(forward) and 50-ATCTTCTTGCTCTAAATCTCC-30 (reverse).
ChIP-Seq and RNA-Seq analysis. ChIP-seq43 and Small RNA-seq8 were
performed as described previously using same standards and quality controls.
ChIP-Seq. Brieﬂy, DN cells were isolated from Bl.6 Rag2 / mice and cross-
linked with 1% formaldehyde. Histone ChIPs were performed by using cross-
linked nuclear extracts from 5 million cells with 2 mg speciﬁc antibodies and 20 ml
Dynabeads Protein G suspension (Life Technologies, USA), whereas 50 million
cells were used for Pol II ChIPs. Antibodies used are described in Koch et al., with
the exception of H3K27ac (ab4729; Abcam). DNA was extracted from immuno-
precipitated chromatin and was used to prepare sequencing library using TrueSeq
ChIP-seq Library Preparation Kit (Illumina Inc., USA) according to manufacturer’s
instructions, and sequenced on a Genome Analyzer II sequencing platform (Illu-
mina Inc., USA). Data processing, including input subtraction and wig ﬁles gen-
eration was performed as previously described43.
Small RNA-Seq. Total RNA was extracted from DN cells isolated from Rag2 /
cells using TriZol Reagent (Life Technologies, USA). Total RNA of 10 mg was
fractionated by TBE-Urea PAGE to isolate RNA fragments ranging from 15
nucleotides to 70 nucleotides length. These size-selected small RNAs were
used to prepare sequencing library using Small RNA-Seq Library Preparation Kit
(Illumina Inc., USA) according to manufacturer’s instructions. Libraries were then
sequenced on a Genome Analyzer II sequencing platform (Illumina Inc., USA).
The RNA-Seq data used is accessible in gene omnibus under the accession number
GSE44578.
OP9-DL1 co-culture assays and in vitro cultures. 4 104 sorted WT or Vav-
CreNfatc1aAﬂ/ﬂ DN1- DN4 cells were co-cultured on monolayers of OP9 stromal
cells expressing the Notch ligand delta-like 1 (OP9-DL1) in X-vivo 20 medium
supplemented with rhFLT3 ligand (5 ngml 1) and rhIL-7 (1 ngml 1) for 4 days.
Subsequently, thymocytes were analysed for differentiation into DP cells by ﬂow
cytometry. In vitro cultures of sorted DN1–DN4 cell populations or CD4þ T cells
were performed either in medium (RPMI-1640, 10% FCS) only or with CsA
(100 ngml 1), 8-CPT-cAMP (50 mM), Forskolin (Fsk; 100mM), CD48 (5 or
0.5 mgml 1), PMA (100 ngml 1), Fibronectin (Fibr; 1 mgml 1) supplemented
with rhIL-7 (10 ngml 1).
Semiquantitative RT–PCR. For RT–PCR, cDNA was synthesized from cells either
freshly isolated or cultured as indicated in each case using Miltenyi Biotech cDNA
synthesis kit. To check CD2-CD48 signalling-induced Nfatc1 expression, 1 106
sorted WT DN3 cells were cultured in cRPMI-1640 medium (10% fetal calf serum)
supplemented with 10 ngml 1 rhIL-7. Cells were either left unstimulated or
stimulated with plate bound CD48 antibodies (5 mg), PMA (100 ng) or with
CD48þPMA for 12 h at 37 C. Similarly, 8 106 CD4þ T cells from lymph nodes
of WT mice were left unstimulated or stimulated with plate bound Fibronectin
(1 mg), CD48 (0.5 mg) or FibronectinþCD48 for 24 h at 37 C. Semiquantitative
RT–PCR was performed to check the levels of expression of indicated genes.
b-actin expression levels were used as control. RT–PCRs to check the expression of
six Nfatc1 isoform were performed using the Fermentas Long distance PCR Kit
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(Cat. # K0181). Primer sequences are available (Supplementary Table 1) in the
Supplemental Information online.
Methylation analysis. Genomic DNA was isolated from FACS sorted WT DN3
and DN4 cells following standard protocol. Sodium bisulphite treatment of
genomic DNA was performed using ZYMO Research EZ DNA Methylation Gold
kit (Cat. # D5005) according to manufacturer’s instructions. All PCR were
performed on MWG AG Biotech Primus 96 plus thermocyclers (Ebersberg,
Germany) in a ﬁnal volume of 25 ml including 1 PCR Master Mix (Thermo
Scientiﬁc, Cat. # K0171), 10 pmol each of forward and reverse primers (Nfatc1 P1d
forward: (-1297 -818) 50-GGAGATTTGAAAGAGAAAAA-30 and Nfatc1 P1d
reverse: (-1297 -818) 50-AAARCTACTCTCCCTTTTAAT-30), and 10 ng of
bisulphite-treated genomic DNA. The following ampliﬁcation protocol was used:
95 C for 10min and 40 cycles of 95 C for 1min, 52 C for 45 s, and 72 C for
1min, and a ﬁnal ampliﬁcation step of 72 C for 10min. PCR products were
eluted and puriﬁed using innuPREP DOUBLEpure kit (Analytik Jena AG, Cat. #
845-KS-5050050) and cloned into a pGEM T-Easy Vector (Promega, Cat. # A1360)
according to manufacturer’s protocol. E. coli (Top-F) were transformed with
plasmid ligates and were selected by ampR on Lurient-Broth Agar plates. Colonies
expressing the full-size ampliﬁcate were detected by blue-white selection and DNA
was prepared according to standard protocols. Positive clones were further
determined by restriction digestion (EcoRI) and subsequently sequenced. PCRs
were performed with primers for T7 and SP6 (Sigma-Aldrich) in both 50 and 30
direction using Big Dye Terminator v3.1 Cycle Sequencing Kit (Applied Biosys-
tems, Product P/N 4336935). Sequence data was generated with an ABI Prism
3130xl, and analysed with BiQ Analyzer v2.0 (Christoph Bock).
Immunoblotting. Positively selected LN CD4þ T cells (2 107) from Nfatc1-
eGfp-Bac tg or Nfatc1-eGfp-Bac-DE2 tg reporter mice were left unstimulated or
stimulated with aCD3 (3mgml 1) plus aCD28 (5 mgml 1) for 48 h. Subsequently,
whole-cell protein extracts were prepared and 20 mg protein from each sample was
subjected to immunoblotting in 12% polyacrylamide gels. Proteins were transferred
to a nitrocellulose membrane followed by immunodetection of GFP with Abs
directed against GFP (Santacruz; sc-9996), or NFATc1a with Abs raised against the
a-peptide of NFATc1 (ImmunoGlobe; IG-457). Images in Fig. 6d are cropped for
presentation excluding the lanes 3 and 6, which represents B-cell extracts. Full-size
images from original scan with molecular weight marker are presented in
Supplementary Fig. 7.
Luciferase reporter assays. One microgram of a murine Ptcra luciferase reporter
construct containing 400 bp enhancer region ( 4,400 to 4,000 bp) and 1.1 kb
DNA fragment spanning murine Ptcra promoter region ( 1034 to þ 66 bp), or
1 mg of a luciferase reporter construct containing 293 bp DNA fragment spanning
murine proximal Il2 promoter region was co-transfected along with 4 mg control
vectors into EL-4 thymoma cells by DEAE/Dextran method. Thirty six hours
post-transfection cells were left unstimulated or stimulated with PMA plus
Ionomycin (100 ngml 1 each, Calbiochem) for 12 h.
Afterwards, luciferase activity representing the Ptcra promoter transactivation
was measured using a MicroLumat LB 96P (EG&G Berthold) luminometer. For
Nfatc1 P1 and P2 promoter constructs, a 1,430 bp (-1155 to þ 275) DNA fragment
in the region around exon 1, and a 1260 bp (-1205 to þ 55) DNA fragment in the
region around exon 2, respectively, were cloned as NheI/XhoI-digested PCR
products into the pGl3basic vector. The potential enhancer elements E1–E4 were
cloned 30 of the luciferase reporter gene as SalI-digested PCR products. Mutations
of potential NFAT, GATA and PU.1 binding sites in the E2 element were
introduced by site-directed mutagenesis. The details about the NFATc1 (Nc1A)
and Notch1 intracellular domain (N1-IC) expression constructs have been
described previously5,44. To assess the effects of NFATc1 activity on Notch-
induced Ptcra promoter activation, 1 106 Jurkat cells were transfected by the
ViaFect Transfection Reagent (Promega, Wisconsin, USA) with 5 mg DNA
containing all necessary constructs according to the manufacturer’s protocol.
Twenty four hours later fresh medium was added and the cells were divided into
untreated or ionomycin (I) treated samples. After further 16 h cells were collected
to estimate luciferase activity.
Data availability. ChIP-Seq (accession numbers GSE80138 and GSE55635) and
RNA-Seq (accession number GSE44578) data are available in the gene omnibus
database. All other data supporting the ﬁndings of this study are available with the
article, and can also be obtained from the authors.
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